Targeted Therapy

In this video interview, Sara M. Tolaney, MD, MPH, discusses the individualized sequential therapies provided to patients based on the breast cancer subtype, genomics and other factors.

In this video interview, Sara M. Tolaney, MD, MPH, discusses the approvals of antibody-drug conjugates and oral targeted agents that improve outcomes among patients with breast cancer.

The most efficacious targeted therapies for VEXAS syndrome are Janus kinase inhibitors and interleukin-6 inhibitors, while IL-1 and TNF blockers are less effective, according to data published in the Annals of the Rheumatic Diseases.

Sikander Ailawadhi, MD, discusses positioning different therapies and navigate the treatment landscape in multiple myeloma.

Healio spoke with Akriti Jain, MD, about the pre-MDS conditions that have the potential to progress into MDS if left untreated.